Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Reporter Solomon Islands.
Press releases published on September 4, 2025
Nusano Announces September Conference Schedule
GlobeNewswire
·
September 4, 2025
WEST VALLEY CITY, Utah, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nusano, a leader in advanced isotope and energy technologies, today announced its September conference schedule. Nusano CEO Chris Lowe will participate in panel discussions and company leadership …
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire
·
September 4, 2025
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative …
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
GlobeNewswire
·
September 4, 2025
NDA remains on track for FDA PDUFA goal date of January 31, 2026 Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “ …
Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases
GlobeNewswire
·
September 4, 2025
Engages Former FDA Director of Division of Cardiology and Nephrology, Norman Stockbridge, M.D., Ph.D., to Advise on Walden’s Clinical Pipeline in Rare Kidney Diseases Utilizes Rare Kidney Disease Patient Advocacy Group to Broaden Awareness and Outreach …
BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)
GlobeNewswire
·
September 4, 2025
Topline Phase 2b Clinical Data Expected in 1H 2026 Trial-in-Progress Presentations Scheduled for ESMO and SNO in Fall 2025 BPM31510 has Received Orphan Drug Designation from the U.S. FDA for the Treatment of GBM BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- …
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO …
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
GlobeNewswire
·
September 4, 2025
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to tirzepatide Nimacimab reduced …
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
GlobeNewswire
·
September 4, 2025
CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Aduro Clean Technologies to Participate in September Conferences and Initiates Public Relations Campaign
GlobeNewswire
·
September 4, 2025
LONDON, Ontario, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste …
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
GlobeNewswire
·
September 4, 2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering …
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the 30th subject in its Expanded Access Program (EAP) of MTX- …
Nano Banana AI - The Ultimate Tool to Edit Images Like a Pro
GlobeNewswire
·
September 4, 2025
LOS ANGELES, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nano Banana AI, the breakthrough AI-powered image editor, is transforming how people edit and create visuals. Built with advanced spatial reasoning, multi-subject awareness, and lifelike rendering, Nano …
ESET Research discovers new Chinese threat group: GhostRedirector manipulates Google, poisons Windows servers with backdoors
GlobeNewswire
·
September 4, 2025
ESET Research observed at least 65 Windows servers compromised, based on an internet scan from June 2025. ESET believes that a previously unknown, China-aligned threat actor is likely behind these attacks. It has been named GhostRedirector by ESET …
Virtune announces that selected crypto ETPs are now available for automatic and commission-free monthly savings
GlobeNewswire
·
September 4, 2025
Stockholm, September 4, 2025 - Virtune today announces that selected crypto ETPs, including for Bitcoin, Ethereum, XRP, and Solana, are now available for monthly savings. This makes it easier than ever for investors to set up a long-term, automatic, and …
Virtune ilmoittaa, että valitut krypto-ETP:t ovat nyt saatavilla automaattiseen ja kuluttomaan kuukausisäästämiseen
GlobeNewswire
·
September 4, 2025
Tukholma, 4. syyskuuta 2025 – Virtune ilmoittaa tänään, että valitut krypto-ETP:t, mukaan lukien Bitcoin-, Ethereum-, XRP- ja Solana-ETP:t, ovat nyt saatavilla kuukausisäästämiseen. Tämä mahdollistaa pitkäjänteisen, automaattisen ja kuluttoman …
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced …
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
GlobeNewswire
·
September 4, 2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s transition into a clinical-stage …
Factures fournisseurs : Lufthansa Group Business Services choisit Esker pour optimiser sa performance et sa croissance à l’international
GlobeNewswire
·
September 4, 2025
Lyon, France - 04 septembre 2025 - Esker, pionnière des solutions d’Agentic AI dédiées à l’Office of the CFO, annonce aujourd’hui que Lufthansa Group Business Services (LGBS) a choisi Esker Accounts Payable (cycle S2P - fournisseurs) pour rationaliser ses …
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present …
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
GlobeNewswire
·
September 4, 2025
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic …